Literature DB >> 194366

Rejectability of virus-induced tumors and nonrejectability of spontaneous tumors: a lesson in contrasts.

G Klein, E Klein.   

Abstract

In contrast to the excellent surveillance against tumors induced by the ubiquitous viruses in their natural host species, spontaneous tumors developing naturally, without experimental interference, evoke little or no rejection reaction. This may be viewed in relation to the natural history of tumors. In most cases, tumors evolve in several steps, with a successful of clonal variants following each other, characterized by increasing independence of host regulations (including immune restrictions). This process is commonly designated as tumor progression. In all probability, selection for nonrejectability is part of this process. Selection of the host for rejecting capacity is unlikely to play any major role, since the overwhelming majority of the naturally occurring tumors arise after the host has passed the peak of its reproductive period. The nonrejectability of spontaneous tumors may be overcome by target-cell modification, e.g., by chemical coupling, somatic cell hybridization, or viral xenogenization. Furthermore, genetic analysis of the F1 resistance effect in relation to seemingly nonrejectable tumors may reveal the existence of specific immune-response (Ir) genes that can influence the recognition of tumor-associated membrane changes by the host immune system.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 194366

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  13 in total

Review 1.  Bone marrow transplantation: the genetic and cellular basis of resistance to engraftment and acute graft-versus-host disease.

Authors:  J Ferrara; P Mauch; G Murphy; S J Burakoff
Journal:  Surv Immunol Res       Date:  1985

2.  A model of the role of natural killer cells in immune surveillance--II.

Authors:  S J Merrill
Journal:  J Math Biol       Date:  1983       Impact factor: 2.259

3.  Preferential expression of IgG1 antibodies specific for L2C leukaemia IgM idiotypic determinants in tumour-protected strain 2 guinea-pigs.

Authors:  M J Ricardo; D T Grimm
Journal:  Immunology       Date:  1983-04       Impact factor: 7.397

4.  Tumour-associated antigens.

Authors:  R W Baldwin
Journal:  Z Krebsforsch Klin Onkol Cancer Res Clin Oncol       Date:  1977-05-20

Review 5.  Modulation of antitumor immunity--immunobiologic approaches.

Authors:  R J North; E S Dye; C D Mills; J P Chandler
Journal:  Springer Semin Immunopathol       Date:  1982

Review 6.  Tumor cells do not arise frequently.

Authors:  W Den Otter
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

7.  Virus-induced hepatocellular carcinomas cause antigen-specific local tolerance.

Authors:  Gerald Willimsky; Karin Schmidt; Christoph Loddenkemper; Johanna Gellermann; Thomas Blankenstein
Journal:  J Clin Invest       Date:  2013-02-01       Impact factor: 14.808

Review 8.  Immunology of metastasis. Can the immune response cope with disseminated tumor?

Authors:  P Frost; R S Kerbel
Journal:  Cancer Metastasis Rev       Date:  1983       Impact factor: 9.264

9.  Specific immunoprophylaxis in experimental tumour-host systems.

Authors:  M D Prager; W C Gordon
Journal:  Can Med Assoc J       Date:  1980-04-05       Impact factor: 8.262

Review 10.  Tumor progression in metastasis: an experimental approach using lectin resistant tumor variants.

Authors:  R S Kerbel; J W Dennis; A E Largarde; P Frost
Journal:  Cancer Metastasis Rev       Date:  1982       Impact factor: 9.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.